StreetInsider.com News Articles

Tempus AI signs multi-year oncology data deal with Bristol Myers Squibb

Fri, 23 Oct 2026 09:01:54 -0400

Tempus AI (NASDAQ: TEM) announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) under which Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031, according to a press release from the Chicago-based company.

The agreement covers biological and clinical insight identification, drug target discovery, and therapeutic development across Bristol Myers Squibb's oncology portfolio. Under the deal, Bristol Myers Squibb becomes one of Tempus's largest licensors of de-identified oncology data.

Bristol Myers Squibb will also gain access to Tempus's Lens Platform, an AI-based platform for oncology drug development connected to GPU infrastructure. The platform is intended to allow Bristol

Tempus AI signs multi-year oncology data deal with Bristol Myers Squibb

Fri, 23 Oct 2026 09:01:54 -0400

Bristol Myers Squibb will also gain access to Tempus's Lens Platform, an AI-based platform for oncology drug development connected to GPU infrastructure. The platform is intended to allow Bristol

Tempus AI signs multi-year oncology data deal with Bristol Myers Squibb

Fri, 23 Oct 2026 09:01:54 -0400

Bristol Myers Squibb will also gain access to Tempus's Lens Platform, an AI-based platform for oncology drug development connected to GPU infrastructure. The platform is intended to allow Bristol

Pathos AI strikes deals with Bristol Myers Squibb and Tempus AI

Fri, 23 Oct 2026 09:01:45 -0400

Pathos AI has announced multi-year collaborations with Bristol Myers Squibb (NYSE: BMY) and Tempus AI (NASDAQ: TEM) focused on building AI-driven capabilities for Alzheimer's disease and other neurological conditions, according to a company press release.

Under a five-year, $55 million agreement, Tempus will construct a de-identified, longitudinal dataset drawn from hundreds of thousands of patients with neurological conditions. Pathos AI will license this dataset and apply its agentic AI platform, Pathos Foundry, to analyze disease biology and inform clinical trial design.

Bristol Myers Squibb is leading Pathos AI's Series E financing round, the terms of which were not disclosed. As part of

Pathos AI strikes deals with Bristol Myers Squibb and Tempus AI

Fri, 23 Oct 2026 09:01:45 -0400

Bristol Myers Squibb is leading Pathos AI's Series E financing round, the terms of which were not disclosed. As part of

Pathos AI strikes deals with Bristol Myers Squibb and Tempus AI

Fri, 23 Oct 2026 09:01:45 -0400

Bristol Myers Squibb is leading Pathos AI's Series E financing round, the terms of which were not disclosed. As part of

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Fri, 23 Oct 2026 09:00:34 -0400

Oct 23 (Reuters) - Pathos ‌AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to ‌develop artificial intelligence tools for drug development in ⁠Alzheimer's disease and other neurological disorders.

Pathos AI also raised $237 million ‌in a Series E ‌funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Fri, 23 Oct 2026 09:00:34 -0400

Pathos AI also raised $237 million ‌in a Series E ‌funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Fri, 23 Oct 2026 09:00:34 -0400

Pathos AI also raised $237 million ‌in a Series E ‌funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Fri, 23 Oct 2026 09:00:34 -0400

Pathos AI also raised $237 million ‌in a Series E ‌funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.

Form 8-K Tempus AI, Inc. For: Oct 23